Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study - Wikidata - awgldk - TriplyDB

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study

http://www.wikidata.org/entity/Q33434137

about

Prolonged complete hematologic response in relapsed/refractory T-large granular lymphocyte leukemia after bendamustine treatment.

P2860

Q42364241-52DA2FDB-05ED-4A27-B9E8-2E2AB061906D

P2860

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study

http://www.wikidata.org/entity/Q33434137

description

2016 nî lūn-bûn

@nan

2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Bendamustine for the treatment ...... etrospective multicenter study

@ast

Bendamustine for the treatment ...... etrospective multicenter study

@en

type

label

Bendamustine for the treatment ...... etrospective multicenter study

@ast

Bendamustine for the treatment ...... etrospective multicenter study

@en

prefLabel

Bendamustine for the treatment ...... etrospective multicenter study

@ast

Bendamustine for the treatment ...... etrospective multicenter study

@en

P1433

Q33434137-96586EAD-EB69-484C-B048-FA002B91C719

P1476

Q33434137-FB2FD001-AF60-4BAC-9BDF-A7FE3FED36EA

P2093

Q33434137-180EB2FF-A212-45F4-88EC-568E9F313CF5

Q33434137-1A4B7A2C-9E1C-4204-BCC4-C4A65DCCE2FA

Q33434137-2BCC8D07-DA39-4ED9-B33C-5BABE521AEE1

Q33434137-3342958C-590D-40D3-A2EC-64772252139E

Q33434137-3435C97C-5A4C-4220-8A71-13336B385EB1

Q33434137-34FBFAC1-6F16-42D1-B9E5-F3152008877E

Q33434137-37A25C64-3902-440E-9454-B87E1D4CB2FD

Q33434137-3D7D9B21-98DB-4CF1-A469-F24A2BEE6B11

Q33434137-3EB74684-4CED-4555-9AE0-B7AE3892690D

Q33434137-49602AFB-B9AC-493B-B0DA-D91783BA6933

P2860

Q33434137-05F11708-608B-427D-A5DF-7452655433E0

Q33434137-073337FE-D820-442A-85B3-B853FEAE5CA8

Q33434137-0CFB7AB7-DF80-4FAF-8CEE-DF4983F30FFE

Q33434137-0DBC54B4-A254-45A1-9AB9-8526D9167E2A

Q33434137-174FE0EB-33C8-4B23-A00E-C8E4255222EA

Q33434137-1E7069B1-3138-42F2-959C-74F975E84607

Q33434137-24487FFA-7AA9-4605-B0B3-6819B07E424A

Q33434137-24EAABDB-1160-43D2-9CEC-7743C4681CEB

Q33434137-2614A32E-7705-4E93-B334-ED2CEB727368

Q33434137-29C5C4B1-8DBC-47A8-BB93-13AC1761AB7E

P304

Q33434137-1B8FC254-4E92-4723-A2DF-D9282D238760

P31

Q33434137-1C5C02ED-DF90-473C-9EED-8253453519CD

P356

Q33434137-2F0AD1FF-7527-4796-A273-D6061FA50001

P407

Q33434137-FF47EA33-438C-478D-A9D0-47554C6A5E53

P433

Q33434137-FA114661-7A51-4563-B73A-183B1673591E

P478

Q33434137-EC4818F2-3460-45B9-8BB2-97F227FDEE31

P50

Q33434137-08538B38-8D93-46A9-937D-EFDDFDCF5589

Q33434137-2799892C-2F24-47C3-8F74-33E7342AB267

Q33434137-E9E89139-0E47-4F29-8600-DB9903D482E2

Q33434137-FA04E8D9-A840-455F-AA82-A07EBCF65696

P577

Q33434137-37AA5C6C-7282-482E-B9D6-245BB59CC380

P698

Q33434137-CC616C71-5A3B-4815-968F-CE7017776F93

P921

Q33434137-D8439145-A61E-4F02-B711-5585E075A3D0

P932

Q33434137-55B7CCB6-2196-4395-859E-A39B232331B7

P356

ONCOTARGET.10764

P1433

P1476

Bendamustine for the treatment ...... etrospective multicenter study

@en

P2093

Aline Clavert

http://www.w3.org/2001/XMLSchema#string

Anne Parcelier

http://www.w3.org/2001/XMLSchema#string

Anne-Claire Gac

http://www.w3.org/2001/XMLSchema#string

Anne-Dominique Pham

http://www.w3.org/2001/XMLSchema#string

Arnaud Jaccard

http://www.w3.org/2001/XMLSchema#string

Bachra Choufi

http://www.w3.org/2001/XMLSchema#string

Bertrand Joly

http://www.w3.org/2001/XMLSchema#string

Charles Herbaux

http://www.w3.org/2001/XMLSchema#string

Christophe Fruchart

http://www.w3.org/2001/XMLSchema#string

Cédric Rossi

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study

Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.

Bendamustine salvage therapy for T cell neoplasms.

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.

P304

85573-85583

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.10764

http://www.w3.org/2001/XMLSchema#string

P407

P433

51

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Guillaume Cartron

Philippe Gaulard

P577

2016-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27458168

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

5356759

http://www.w3.org/2001/XMLSchema#string